ICD-10-CM Coding for Prior Authorization of Doxepin 3mg
For prior authorization of doxepin 3mg in this patient, use G47.00 (Insomnia, unspecified) as the primary diagnosis code, as this is the specific indication for low-dose doxepin and the condition requiring treatment. 1
Rationale for Code Selection
The American Academy of Sleep Medicine clinical practice guidelines specifically recommend doxepin 3mg and 6mg doses for treatment of sleep maintenance insomnia in adults 1. This is the FDA-approved indication for low-dose doxepin formulations. While your patient has multiple psychiatric comorbidities (ADHD, OCD, anxiety), the prior authorization request should focus on the insomnia diagnosis because:
- Low-dose doxepin (3-6mg) is NOT indicated for depression, anxiety, OCD, or ADHD 2
- The FDA labeling for doxepin distinguishes between high-dose formulations (10-100mg) used for depression/anxiety and low-dose formulations specifically for insomnia 2
- Insurance companies will deny authorization if you code for psychiatric conditions when requesting a sleep medication at this dose
Complete Coding Strategy
Primary Diagnosis Code (Required for Authorization):
- G47.00 - Insomnia, unspecified
Secondary Diagnosis Codes (Supporting Documentation):
You may include these as secondary codes to provide clinical context, but they should NOT be the primary justification:
- F90.2 - Attention-deficit hyperactivity disorder, combined type (or F90.0 for predominantly inattentive, F90.1 for predominantly hyperactive)
- F42.2 - Mixed obsessional thoughts and acts (or F42.8/F42.9 depending on OCD presentation)
- F41.9 - Anxiety disorder, unspecified (or more specific anxiety code if applicable, e.g., F41.1 for generalized anxiety disorder)
Critical Pitfalls to Avoid
Do NOT use F51.01 (Primary insomnia) as the primary code. While this seems logical, G47.00 is the preferred code for insomnia in the context of comorbid psychiatric conditions. The distinction between "primary" and "secondary" insomnia has been eliminated in modern diagnostic frameworks, and chronic insomnia disorder is now recognized as a distinct condition even when psychiatric comorbidities are present 3.
Do NOT list depression codes (F32.x, F33.x) unless your patient actually has diagnosed depression, as this may trigger insurance requirements for antidepressant-dose doxepin (25-300mg) rather than the low-dose sleep formulation 2.
Do NOT use T-codes (poisoning/adverse effect codes) as these are inappropriate for a new prescription request and would likely result in automatic denial 4.
Supporting Documentation for Prior Authorization
When submitting the prior authorization, include documentation that:
- The patient has sleep maintenance insomnia (difficulty staying asleep, not just falling asleep)
- Behavioral interventions (sleep hygiene, CBT-I if attempted) have been considered or tried 3
- The 3mg dose is specifically requested for insomnia treatment per AASM guidelines 1
- The patient's psychiatric comorbidities (ADHD, OCD, anxiety) contribute to or coexist with the insomnia but are not the primary target of doxepin treatment
Additional Clinical Context
Research demonstrates that insomnia disorder is highly prevalent (44.4%) in adult ADHD patients and is associated with greater ADHD severity and psychiatric comorbidity 5. This supports the medical necessity of treating the insomnia as a distinct condition. Interestingly, stable ADHD stimulant treatment is associated with lower rates of insomnia disorder 5, so document whether your patient is on ADHD medication and whether sleep difficulties persist despite optimized ADHD management.
The AASM guidelines provide a conditional (WEAK) recommendation for doxepin 3-6mg for sleep maintenance insomnia, with low to very low quality evidence but benefits outweighing harms 1. This is sufficient evidence-based support for prior authorization purposes.